The stalemate between NHS England and Vertex Pharmaceuticals Inc. over the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) is finally over. The two parties have finally agreed a deal that will give the company better access to the UK, the second biggest market for its cystic fibrosis drugs which also include Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor).
Under the deal announced on 24 October, patients will have access to Orkambi and Symkevi in all current and future...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
